It takes time to find the best antidepressants for some people, so why not use genetics to do it faster?
A unique genetic test created to identify the most effective antidepressant for people with severe and medium depression could significantly enhance patient outcomes and result in substantial savings for the country.
It saves time, money, and also helps people - so it can be a real game-changer.
How It Works
Pharmacogenomic testing aims to match people with medications based on their genetic profile, increasing effectiveness and reducing side effects.
Major depression affects one in 10 Canadians, presenting a significant public health burden.
Despite over 35 available antidepressant medications, more than half of patients don't respond to their initial prescription, with around 27% reporting adverse effects.
Up to 42% of the variability in patient response to antidepressants is due to genetic factors.
Pharmacogenomic testing utilizes genetic information to guide medication selection and dosing, offering a more informed approach than the trial-and-error process.
The simulation experiment showed that pharmacogenomic testing would lead to 36% fewer patients experiencing treatment-resistant depression, along with patients spending 15% more time without depression symptoms.
Why It's Important
A patient partner in the study living with major depression emphasized the importance of genetic testing in providing hope and tailored treatment.
The researchers stress the need for continued exploration of implementation strategies, considering input from patients, physicians, government, and health sector partners.
Previously, we talked about the nature of fear.
